Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GOSS

Gossamer Bio Inc

May 10 • 04:00PM ET

0.7423

Dollar change -0.0033
Percentage change -0.44	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VHT SCHA IWC SCHB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.05	Insider Own	16.27%	Shs Outstand	225.41M	Perf Week	0.31%
Market Cap	167.92M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	0.51%	Shs Float	205.29M	Perf Month	-23.28%
Income	-172.58M	PEG	-	EPS next Q	0.27	Inst Own	80.54%	Short Float	6.26%	Perf Quarter	-14.68%
Sales	0.00M	P/S	-	EPS this Y	71.03%	Inst Trans	11.75%	Short Ratio	7.38	Perf Half Y	24.76%
Book/sh	0.12	P/B	6.28	EPS next Y	-117.58%	ROA	-72.02%	Short Interest	12.85M	Perf Year	-47.35%
Cash/sh	1.08	P/C	0.69	EPS next 5Y	5.20%	ROE	-480.50%	52W Range	0.45 - 1.88	Perf YTD	-18.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.99%	ROI	-77.20%	52W High	-60.52%	Beta	1.95
Dividend TTM	-	Quick Ratio	7.13	Sales past 5Y	0.00%	Gross Margin	-	52W Low	64.04%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	7.13	EPS Y/Y TTM	57.87%	Oper. Margin	0.00%	RSI (14)	38.14	Volatility	8.15% 10.41%
Employees	135	Debt/Eq	7.82	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.80	Target Price	6.09
Option/Short	Yes / Yes	LT Debt/Eq	7.37	EPS Q/Q	64.16%	Payout	-	Rel Volume	0.60	Prev Close	0.75
Sales Surprise	-	EPS Surprise	0.05%	Sales Q/Q	-	Earnings	May 07 AMC	Avg Volume	1.74M	Price	0.74
SMA20	-2.00%	SMA50	-30.63%	SMA200	-21.01%	Trades		Volume	1,049,737	Change	-0.44%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31
Apr-22-20	Initiated	Piper Sandler	Overweight	$30
Feb-27-20	Initiated	Barclays	Overweight	$21
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy	$31

Show Previous Ratings

May-10-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-24 10:56PM	GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 (InvestorPlace) -6.30%
05:15PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
05:11AM	Gossamer Bio and Chiesi partner for pulmonary hypertension treatment (Pharmaceutical Technology)
04:31AM	Loading…
04:31AM	Gossamer Bio and Chiesi link for pulmonary hypertension treatment (Pharmaceutical Technology)
May-06-24 03:17PM	Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide (Benzinga) +5.50%
08:17AM	UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (Reuters)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
07:41AM	Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment (Reuters)
07:30AM	Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications (Business Wire)
May-03-24 08:02AM	Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine (Business Wire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
10:52PM	Loading…
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 10:53AM	5 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.24%
Dec-13-23 04:01PM	Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 (Business Wire)
Dec-05-23 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31%
07:01AM	Gossamer Bio Appoints Bob Smith as Chief Commercial Officer (Business Wire)
Nov-29-23 07:01AM	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors (Business Wire)
Nov-09-23 08:11AM	Gossamer Bio Inc (GOSS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.56%
07:41AM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
10:08AM	Loading…
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -6.46%
Oct-03-23 04:08PM	Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs (Business Wire) -5.57%
Sep-07-23 07:44AM	Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 (Business Wire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-08-23 04:41PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance) -5.43%
04:01PM	Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-24-23 04:16PM	Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results (Business Wire)
Jul-20-23 07:56AM	Gossamer Bio Announces $212 Million Private Placement Financing (Business Wire) -31.87%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
May-18-23 07:05AM	Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference (Business Wire) +7.58%
May-13-23 08:15AM	In the wake of Gossamer Bio, Inc.'s (NASDAQ:GOSS) latest US$15m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
May-09-23 04:13PM	Gossamer Bio: Q1 Earnings Snapshot (AP Finance)
04:01PM	Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Apr-04-23 12:38PM	After Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma Candidate (Benzinga) -9.38%
Mar-17-23 07:46AM	Gossamer Bio: Q4 Earnings Snapshot (AP Finance) -8.47%
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update (Business Wire)
Mar-07-23 03:37PM	Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success (Benzinga)
Mar-03-23 11:40AM	15 Most Shorted Stocks Right Now on Wall Street (Insider Monkey)
Feb-01-23 04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace) +7.20%
Jan-04-23 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.39%
09:35AM	Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-26-22 09:41AM	Bullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this year (Simply Wall St.)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga) -74.60%
10:00AM	Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation (Benzinga)
08:19AM	Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug (MarketWatch)
07:15AM	Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH (Business Wire)
Nov-17-22 02:37PM	Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial (Benzinga)
Nov-08-22 12:00PM	What Makes Gossamer Bio (GOSS) a New Buy Stock (Zacks)
Nov-03-22 04:01PM	Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Oct-24-22 08:30AM	Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential (TipRanks)
Aug-29-22 08:11AM	With 62% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners (Simply Wall St.)
Aug-09-22 08:01AM	Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Jul-21-22 06:21PM	2 Strong Buy Stocks That In-The-Know Bigwigs Are Pouring Money Into (TipRanks)
Jul-20-22 11:33AM	Squeezable AMC, GameStop stocks break out to multi-month highs (MarketWatch)
Jul-19-22 12:00PM	Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy (Zacks) +6.29%
09:46AM	The Co-Founder of Gossamer Bio, Inc. (NASDAQ:GOSS), Faheem Hasnain, Just Bought 3.8% More Shares (Simply Wall St.)
Jul-18-22 09:55AM	Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High? (Zacks)
Jul-13-22 07:15AM	Gossamer Bio Announces $120 Million Private Placement Financing (Business Wire) +31.90%
Jun-09-22 08:30AM	Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinibs Potential for the Treatment of PAH (Business Wire)
May-26-22 09:55AM	Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade (Zacks)
May-23-22 09:55AM	Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-10-22 04:01PM	Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update (Business Wire) +11.70%
May-06-22 12:20PM	Is Gossamer Bio (NASDAQ:GOSS) Weighed On By Its Debt Load? (Simply Wall St.) -7.01%
Apr-25-22 07:29AM	Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update (Business Wire)
Mar-03-22 04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update (Business Wire)
Feb-28-22 07:01AM	Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022 (Business Wire)
Jan-02-22 08:47AM	What Kind Of Investors Own Most Of Gossamer Bio, Inc. (NASDAQ:GOSS)? (Simply Wall St.)
Nov-08-21 04:01PM	Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Nov-02-21 04:01PM	Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021 (Business Wire)
Oct-11-21 08:36AM	Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 (Business Wire) +6.52%
Oct-07-21 04:01PM	Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021 (Business Wire)
Oct-03-21 10:45AM	Is Gossamer Bio (NASDAQ:GOSS) Weighed On By Its Debt Load? (Simply Wall St.)
Sep-21-21 08:31AM	Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role (Business Wire) +10.63%
Aug-09-21 04:01PM	Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Aug-02-21 04:01PM	Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 (Business Wire)
Jul-21-21 05:16AM	Hedge Funds Are Selling Gossamer Bio, Inc. (GOSS) (Insider Monkey)
Jul-17-21 05:47AM	Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Increased Their Holdings (Simply Wall St.)
Jul-07-21 07:01AM	Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohns and Colitis Organisation (Business Wire)
Jun-21-21 04:01PM	Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer (Business Wire)
Jun-14-21 04:01PM	Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors (Business Wire)
May-06-21 07:31AM	Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Apr-20-21 07:50AM	Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer (Business Wire)
Apr-16-21 07:55AM	Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs (Business Wire)
Feb-25-21 07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update (Business Wire) -5.59%
Feb-19-21 08:01AM	Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021 (Business Wire)
Feb-04-21 07:05AM	Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021 (Business Wire)
Jan-18-21 03:05AM	Have Insiders Been Buying Gossamer Bio, Inc. (NASDAQ:GOSS) Shares This Year? (Simply Wall St.)
Dec-19-20 03:54PM	Is GOSS A Good Stock To Buy Now According To Hedge Funds? (Insider Monkey)
Dec-11-20 05:00PM	Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial (GlobeNewswire)
Dec-07-20 07:03AM	Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020 (Business Wire)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hasnain Faheem	President & CEO	Mar 27 '24	Sale	1.16	23,172	26,773	120,293	Mar 28 06:01 PM
Giraudo Bryan	COO/CFO	Mar 27 '24	Sale	1.16	6,430	7,431	92,737	Mar 28 06:05 PM
Christian Waage	EVP, Tech Ops and Admin	Mar 27 '24	Sale	1.16	6,430	7,430	585,934	Mar 28 06:16 PM
Peterson Caryn	EVP, Regulatory Affairs	Mar 18 '24	Sale	1.33	4,018	5,343	49,833	Mar 19 06:50 PM
Aranda Richard	Chief Medical Officer	Mar 18 '24	Sale	1.33	4,018	5,342	198,799	Mar 19 06:50 PM
Milligan Sandra	Director	Nov 15 '23	Buy	0.79	32,000	25,213	32,000	Nov 17 04:01 PM
Giraudo Bryan	COO/CFO	Nov 13 '23	Buy	0.56	200,000	112,880	380,010	Nov 14 06:24 PM
Aranda Richard	Chief Medical Officer	Jun 22 '23	Sale	1.29	1,814	2,340	197,574	Jun 26 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GOSS

Gossamer Bio Inc

Upgrade your FINVIZ experience